Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    172
    ...
ATC Name B/G Ingredients Dosage Form Price
C08CA01 AMLOR B Amlodipine besylate - 5mg 5mg Capsule 560,382 L.L
L01BC06 XELODA B Capecitabine - 500mg 500mg Tablet, film coated 17,946,398 L.L
M02AA31 ROXONIN TAPE B Loxoprofen Sodium Hydrate - 50mg 50mg Patch 710,893 L.L
M09AX10 EVRYSDI B Risdiplam - 0.75mg/ml 0.75mg/ml Powder L.L
B05XB02 DIPEPTIVEN B L-alanine-L-Glutamine - 20g/100ml 20g/100ml Injectable concentrated solution 2,940,456 L.L
C08CA01 AMLOR B Amlodipine besylate - 5mg 5mg Capsule 560,382 L.L
G02BA NUVARING B Etonogestrel - 0.12mg/day, Ethinylestradiol - 0.015mg/day Ring 1,052,229 L.L
S01EA05 LUMIFY B Brimonidine tartrate - 0.025% Drops solution 1,888,099 L.L
G02BA03 MIRENA 20mcg/24h Levonorgestrel B Levonorgestrel - 20mcg/24h 20mcg/24h Implant 10,530,753 L.L
H02AB04 SOLU MEDROL B Methylprednisolone sodium succinate - 500mg 500mg Injectable powder for solution 718,956 L.L
J01DD08 SUPRAX B Cefixime (trihydrate) - 400mg 400mg Capsule 2,053,391 L.L
M03AC11 NIMBEX B Cisatracurium (besylate) - 20mg/10ml 20mg/10ml Injectable solution 2,010,388 L.L
N02BE51 PANADOL NIGHT B Paracetamol - 500mg, Diphenhydramine HCl - 25mg 500mg Caplet 315,803 L.L
N06DA02 ARICEPT B Donepezil HCl - 5mg 5mg Tablet, film coated 3,254,787 L.L
S01EA05 ALPHAGAN P B Brimonidine tartrate - 0.1% 0.15% Drops solution 999,819 L.L
A03FA03 MOTILIUM B Domperidone - 10mg 10mg Tablet 353,431 L.L
G02CB03 DOSTINEX B Cabergoline - 0.5mg 0.5mg Tablet, scored 415,247 L.L
J01DD08 SUPRAX B Cefixime (trihydrate) - 400mg 400mg Capsule 2,053,391 L.L
M03AC11 NIMBEX B Cisatracurium (besylate) - 20mg/10ml 20mg/10ml Injectable solution 2,010,388 L.L
N02BE51 PANADOL SINUS B Paracetamol - 500mg, Pseudoephedrine HCl - 30mg Caplet 228,453 L.L
S01EB02 MIOSTAT STERIL INTRAOCULAR B Carbachol - 0.01% 0.01% Solution 8,117,591 L.L
S01LA09 VABYSMO B Faricimab - 6mg/0.05ml 6mg/0.05ml Injectable solution L.L
G02CB03 DOSTINEX B Cabergoline - 0.5mg 0.5mg Tablet, scored 1,628,737 L.L
H02AB04 SOLU MEDROL B Methylprednisolone sodium succinate - 1g 1g Injectable powder for solution 1,444,631 L.L
C09DB02 SEVIKAR B Olmesartan medoxomil - 20mg, Amlodipine - 5mg Tablet, film coated 1,019,976 L.L
N02BE51 PANADOL COLD & FLU DAY B Paracetamol - 500mg, Caffeine - 25mg, Phenylephrine HCl - 5mg Caplet 284,895 L.L
R03DX10 FASENRA B Benralizumab - 30mg 30mg Injectable solution L.L
C09DB02 VOCADO B Olmesartan medoxomil - 20mg, Amlodipine besylate - 5mg Tablet, film coated 971,598 L.L
H02AB04 DEPO MEDROL B Methylprednisolone acetate - 40mg/ml 40mg/ml Injectable suspension 182,763 L.L
N02BE51 PANADOL COLD & FLU ALL IN ONE B Paracetamol - 250mg, Guaifenesin - 100mg, Phenylephrine HCl - 5mg Tablet, film coated 342,680 L.L
    ...
    172
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025